STAGE IIIC BREAST CANCER
Clinical trials for STAGE IIIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIC BREAST CANCER trials appear
Sign up with your email to follow new studies for STAGE IIIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine aims to train immune system against breast cancer stem cells
⭐️ VACCINE ⭐️ OngoingThis early-stage trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer whose disease is stable or gone after standard treatment. The vaccine is designed to help the immune system recognize and attack cancer stem cells, which are often res…
Matched conditions: STAGE IIIC BREAST CANCER
Phase: PHASE1 • Sponsor: University of Washington • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 22, 2026 12:03 UTC
-
New chemo combo shows promise for tough breast cancer
Disease control OngoingThis phase II trial tests whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The study aims to increase the rate of complete remission (no cance…
Matched conditions: STAGE IIIC BREAST CANCER
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Can a drug combo shrink breast tumors better before surgery?
Disease control OngoingThis phase 3 trial tests whether giving fulvestrant alone or with anastrozole before surgery works better than anastrozole alone for postmenopausal women with estrogen receptor-positive breast cancer. Over 1,400 participants will receive one of these hormone therapies for several…
Matched conditions: STAGE IIIC BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New hope for Hard-to-Treat breast cancer: immune cocktails enter trial
Disease control OngoingThis phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…
Matched conditions: STAGE IIIC BREAST CANCER
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Could adding carboplatin beat triple-negative breast cancer?
Disease control OngoingThis study tests whether adding a drug called carboplatin to standard chemotherapy helps people with triple-negative breast cancer live longer without the cancer coming back. About 782 patients with high-risk or node-positive disease took part. The goal is to see if the stronger …
Matched conditions: STAGE IIIC BREAST CANCER
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
Can adding a targeted drug shrink breast tumors before surgery?
Disease control OngoingThis study tests whether giving chemotherapy (paclitaxel and cyclophosphamide) with or without the targeted drug trastuzumab before surgery can shrink breast tumors and reduce the amount of tissue that needs to be removed. It includes 92 women with early-stage or locally advanced…
Matched conditions: STAGE IIIC BREAST CANCER
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New PET scan could predict which breast cancer patients respond to targeted therapy
Diagnosis OngoingThis phase 2 trial is testing whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to trastuzumab and pertuzumab before surgery. The study involves 18 women with locally advanced HER2-positive breast cancer. The g…
Matched conditions: STAGE IIIC BREAST CANCER
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 23, 2026 12:09 UTC